| Document |
Document Title |
|
JPH0141314B2 |
An unfiltered fermentation broth which has been produced by Claviceps purpurea strains is extracted with organic solvents which have no more than limited miscibility with water. In order to simplify the extraction, the fermentation broth...
|
|
JPS6468322A |
PURPOSE: To obtain a composition for increasing a serotonergic function, comprising a 2,3-dihydroergoline compound, a diluent and a carrier, having an action for increasing the endogenous serotonergic function, and useful for an antidepr...
|
|
JPS6422875A |
NEW MATERIAL: The compd. of formula I [R1 is H or CH3; R2 is H, hologram, CH3, cyano, phenyl, etc.; R3 is 1 to 4C hydrocarbon group; R4 is H, phenyl, R3; R6, R7 form a valence bond together with H or R6 and R7; R8 is H, OCH3 or R6 is H, ...
|
|
JPS6363544B2 |
Novel ergoline compounds of the following formula are described:wherein R1 is ethyl, n-propyl, or allyl; Y is O, S, SO, or SO2; X is hydrogen, chloro, or bromo; the dotted line represents the optional presence of a double bond; and the p...
|
|
JPS63297380A |
The present invention provides novel bicyclic ergoline esters useful as serotonin antagonists.
|
|
JPS63258819A |
Selective dopamine D1 receptor agonists for use in the treatment of primary degenerative dementia, depression, anxiety, obesity or schizophrenia.
|
|
JPS63222170A |
Ergoline derivatives of the formula I wherein R1 represents a hydrogen atom or a methyl group; R2 represents a hydrogen atom or a methoxy group; R3 represents a hydrocarbon group having from 1 to 4 carbon atoms; X represents a nitrogen a...
|
|
JPS63119483A |
Compounds of the formula I in which Ar represents an optionally substituted aryl or hetaryl radical and R<6> denotes lower alkyl and can be a single or double bond, and their acid addition salts are described. These compounds have useful...
|
|
JPS6313996B2 |
|
|
JPS6330485A |
Compounds of the formula I : wherein R1 =H, CH3; m = 0,1; R2 = R3 = H or R2, R3 = bond, R4 = C1-C4 hydrocarbon, n = 1 or 2 and their pharmaceutically acceptable salts are antihypertensive agents. Their preparation and pharmaceutical comp...
|
|
JPS632265B2 |
3-(8-Ergolinyl)-1,1-diethylurea derivs. of formula (I) and their salts are new (where R is 2-6C alkyl). (I) have higher dopaminergic activity than lisuride hydromaleate and can be used, e.g. for inhibiting lactation and treating Parkinso...
|
|
JPS6254769B2 |
A method for the treatment of congestive heart failure in animals comprises administering a therapeutically effective amount of an ergolene or ergoline having dopaminergic activity to an animal in need of such treatment.
|
|
JPS6245870B2 |
8-beta-Acetylergoline derivs (I) are new (where R=H or CH3; R1=H or OCH3; R2=pyridyl, pyrazinyl, or pyridazinyl or phenyl opt. substd. by Cl, Br, F, 1-4C alkoxy, CH3 or CF3). The cpds. are useful as anxiolytics and neuroleptics. (I) is p...
|
|
JPS6239158B2 |
A process for the production of a compound of formula I wherein R1 is carboxyl, alkoxy- (C1-5)carbonyl, amido, alkyl(C1-5)amido, di(alkyl(C1-5))amido or an amido radical of formula II wherein Ra is alkyl(C1-4), Rb is alkyl(C1-4) or benzy...
|
|
JPS62190123A |
Low molecular weight quinolines, e.g. ergolines, have been found to have immunosuppressant properties.
|
|
JPS62190184A |
Novel compounds of the formula I wherein R1 is hydrogen or (C1-4)alkyl, R2 is CN, COOH, COOR5, CONH2, CONHR5, CON(R5)R6, SR5, SOR5, SO2R5, CHO, CH2OH, COR7, CH2R7', CH(OH)R5, CH2CF3, iodine, C IDENTICAL CR8, CH=CHR8, (C2-12)alkyl, NO2, N...
|
|
JPS62174074A |
Novel 2-substituted ergolinyl urea and thioruea derivatives are disclosed, as well as their use as pharmaceuticals, specifically as neuroleptics. The compounds, which possess central dopaminergic activity, have the formula (I) wherein X ...
|
|
JPS62158279A |
Cyclic ether esters of 1-substituted-6-C1-4 straight chain alkyl (or allyl)ergoline-8 beta -carboxylic acid, useful as 5HT receptor antagonists.
|
|
JPS6228794B2 |
Novel 2-azaergolines, 2-aza-8(or 9)-ergolenes, which are neuroleptic agents, are described herein. These compounds are prepared by reacting a 7-amino-6-ketobenzo[f]quinoline with a diazotization agent. e.g. sodium nitrite and a strong mi...
|
|
JPS6225149B2 |
A method for preparing ergoline derivatives in which the ergoline structure is variously substituted by morpholino-piperazino- and other active radicals to obtain novel compounds useful in cardiology as alpha-blocking, vasodilating, anti...
|
|
JPS6222995B2 |
|
|
JPS6221792B2 |
The novel ergoline derivatives of the general formula I wherein R1 represents an ally or alkoxy group having from 1 to 4 carbon atoms, phenyl, a 5- or 6-membered heterocyclic ring which is preferably saturated, an amino group, a substitu...
|
|
JPS6296488A |
Ergolinylthioureas derivatives of the general Formula I (I) wherein R1 is hydrogen, lower alkyl or acyl, R2 is hydrogen, halogen or a lower alkylthio group R3 is lower alkyl, R4, R5 and R6, is hydrogen or lower alkyl, and each is identic...
|
|
JPS6213956B2 |
The invention relates to the method for producing ergoline derivatives or the salts thereof with organic or inorganic acids. The compounds of the given formula are added into the reaction mixture followed by the isolation of the end-prod...
|
|
JPS628433B2 |
There are provided ergoline derivatives of formula wherein R1=H, CH3; R2=H or halogen atom, or CH3,CN, alkyl- or phenyl-thio; R3=H, OCH3; R4=C1-C4 hydrocarbon group; X=O, S, NH; A=CO, SO2; B=C1-C4 hydrocarbon group, aryl, aralkyl, hetero...
|
|
JPS62464A |
D-2-Alkyl (or phenyl) thio-6-n-alkylergolines or +/--2-alkyl(or phenyl)thio-4-dialkylaminotetrahydrobenz [c,d]indoles as dopamine D-1 antagonists.
|
|
JPS6159289B2 |
|
|
JPS61286382A |
A composition for the treatment of endometritis in mammalian females which comprises as the physiologically active component a 1-(8alpha-ergolinyl)-3,3-diethylurea of the general formula I in which R<1> represents an alkyl group containi...
|
|
JPS6139928B2 |
|
|
JPS61186381A |
1. A process for the production of ergoline derivatives of the general formula I see diagramm : EP0190534,P5,F1 wherein C8 _-_-_-_-_-_-_- C9 and C9 _-_-_-_-_-_-_- C10 are each a CC-single bond or each is a separate C = C-double bond, R**...
|
|
JPS6133031B2 |
The present invention provides compounds of formula I, I wherein X is hydrogen, chlorine or bromine, R1 is methyl or ethyl, R2 is alkyl of 1 to 4 carbon atoms or allyl, R3 is CH2CN or a group -NR4R5, wherein R4 is hydrogen or alkyl of 1 ...
|
|
JPS6132316B2 |
|
|
JPS61158980A |
Compounds of formula I (I) wherein R1 is hydrogen or C1-4alkyl, R2 is hydrogen, chlorine, bromine or methyl, R3 is C1-5alkyl or C3-5alkenyl and R4 is C1-7alkyl; C3-7cycloalkyl; adamantyl; or optionally substituted phenyl, are useful as n...
|
|
JPS61140584A |
N-1-subs@@tuted-6-n-propyl-8 beta -methylthiomethylergoline@@e D-2 agonists which do not interact with alpha adrenergi@receptors.
|
|
JPS61112074A |
There is described a compound of the formulain which R1 is hydrogen or C1-4 alkyl, R2 is hydrogen, C1-4 alkyl, hydroxy C1-4 alkyl, C1-4 alkoxy C14 alkyl, HSC1-4 alkyl, C1-4 alkyl-S-C1-4 alkyl, C1-4 alkylthio, optionally substituted arylt...
|
|
JPS6143189A |
There are disclosed pharmaceutical compounds of the formulain which R' is an aliphatic or aromatic function, and R2 and R3 are each hydrogen, C1-4 alkyl or a protecting group ; and salts thereof.
|
|
JPS60237019A |
Terguride and its physiologically compatible salts have been discovered to be useful in the treatment of essential hypertonia, e.g., in humans, e.g., in doses of 0.1-1.0 mg/day.
|
|
JPS60197687A |
4,6,6a,7,8,12b-hexahydro-indolo[4,3-ab]phenanthridines are useful as dopaminergic and analgesic agents.
|
|
JPS6027676B2 |
There are prepared compounds having good adrenolytic, hypotonic, analgesic, central-sedative and antiserotoninic activity of the formula III in which R denotes hydrogen or methyl; R1 and R2 in each case denote hydrogen, alkyl having 1 to...
|
|
JPS6018662B2 |
|
|
JPS6017795B2 |
6-Methyl-8-(substituted)methylergolines, useful as prolactin inhibitors.
|
|
JPS6038382A |
R1 = CH3, phenyl, piperidino, 1-pyrrolidinyl, morpholino, 4-methyl-1-piperazinyl, C1-C4alkyl, C1-C4alkoxy, NH2, NHR min (R min =C1-C4alkyl, cycloalkyl, benzyl or phenyl) or NR sec R''' (R sec and R''' independently = C1-C4alkyl), R2 = H,...
|
|
JPS604833B2 |
|
|
JPS5946235B2 |
6-Methyl-8-(substituted)methylergolines, useful as prolactin inhibitors.
|
|
JPS59176285A |
Substituted ergolines of the formula and their acid addition salts, wherein the urea side chain in the 8-position can be in the d alpha - or beta -configuration, C2 C3 and C9 C10 are a CC single or C=C double bond, and R is hydrogen or N...
|
|
JPS59175431A |
A pharmaceutical use of a class of ergoline compounds of the formula wherein: R is C1-C3 alkyl or allyl; R<1> is C1-C3 hydroxyalkyl or C1-C3 dihydroxyalkyl; R<2> is H or methyl; or a pharmaceutically-acceptable salt thereof, as 5HT2 rece...
|
|
JPS5940833B2 |
9,10-Dihydrolysergic acid-(3'-/pyrrolid-2''-on-1'-yl/-propyl)-amide, 1-methyl-9,10-dihydrolysergic acid-(thiazoline-2'-yl)-amide and lysergic acid-(3'-allyloxy-2'-oxy-propyl)-amide and their pharmaceutically acceptable acid addition salt...
|
|
JPS5939434B2 |
The present invention relates to compounds of the following formula R1 N ANGLE ¦ R2¦NO ANGLE ¦ ANGLE N-(Y)-C-Ar R3 I wherein Y is straight or branched chain alkylene containing 1-4 carbon atoms; R1 is lower alkyl containing 1-7 carbon...
|
|
JPS5936636B2 |
|
|
JPS5936631B2 |
The present invention relates to compounds of the following formula R1 N ANGLE ¦ R2¦NO ANGLE ¦ ANGLE N-(Y)-C-Ar R3 I wherein Y is straight or branched chain alkylene containing 1-4 carbon atoms; R1 is lower alkyl containing 1-7 carbon...
|
